Search

Your search keyword '"Castagna, L"' showing total 946 results
Start Over Author "Castagna, L"

Refine your results

more »

more »

more »

more »
946 results on '"Castagna, L"'

201. A prospective phase II study on tandem autografting - Nonmyeloablative allografting for newly diagnosed multiple myeloma: Final results of a multicenter GITMO (Gruppo Italiano Trapianto Midollo Osseo) protocol

Author

Sorasio, R, Patriarca, F, Giaccone, L, Mattei, D, Allione, B, CARNEVALE SCHIANCA, F, Rambaldi, A, Casini, M, Montefusco, V, Parma, M, Bavaro, F, Onida, F, Busca, A, Castagna, L, Lori, Ap, Rotta, M, Fiore, F, Benedetti, E, Mordini, N, Massaia, M, Palumbo, A, Aglietta, M, Lewis, A, Foa, R, DI BARTOLOMEO, P, Pogliani, E, LAMBERTENGHI DELILIERS, G, Falma, M, Petrini, M, Corradini, F, Fanin, R, Ricardi, U, Ciccone, G, Baldi, Ileana, Bruno, B, and Boccadoro, M.

Published
2007

202. A PROSPECTIVE PHASE II STUDY ON TANDEM AUTOGRAFTING-ONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL RESULTS OF A MULTICENTER GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) PROTOCOL

Author

Sorasio, R., Patriarca, F., Giaccone, L., Mattei, D., Allione, B., Carnevale Schianca, F., Rambaldi, A., Casini, M., Montefusco, V., Parma, M., Bavaro, P., Onida, F., Busca, A., Castagna, L., Iori, A.P., Rotta, M., Fiore, F., Benedetti, E., Mordini, N., Massaia, M., Palumbo, A., Aglietta, M., Lewis, A., Foà, R., Di Bartolomeo, P., Pogliani, E., Lambertenghi-Deliliers, G., Falda, M., Petrini, M., Corradini, P., Fanin, R., Ricardi, U., Ciccone, G., Baldi, I., Bruno, B., and Boccadoro, M.

Subjects
Settore MED/15 - Malattie del Sangue
Published
2007

203. Tandem autografting-nonmyeloablative allografting for newly diagnosed multiple myeloma: The GITMO (gruppo italiano trapianto midollo osseo) experience

Author

Giaccone, Luisa, Patriarca, F., Rotta, M., Mordini, N., Maloney, D. G., Casini, M., Rambaldi, A., CARNEVALE SCHIANCA, F., Allione, B., Soligo, D., Bavaro, P., Iori, A. P., Sorasio, R., Fiore, F., Montefusco, V., Busca, A., Parma, A., Castagna, L., Benedetti, E., Fanin, R., Gallamini, A., Corradini, P., Levis, A., Aglietta, M., Pogliani, E., Falda, M., Massaia, Massimo, Palumbo, A., Sandmaier, B., Storb, R., Boccadoro, Mario, and Bruno, Benedetto

Published
2007

204. Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial

Author

Blaise, D., primary, Devillier, R., additional, Lecoroller-Sorriano, A.-G., additional, Boher, J.-M., additional, Boyer-Chammard, A., additional, Tabrizi, R., additional, Chevallier, P., additional, Fegueux, N., additional, Sirvent, A., additional, Michallet, M., additional, Bay, J.-O., additional, Furst, S., additional, El-Cheikh, J., additional, Vincent, L., additional, Guillaume, T., additional, Regny, C., additional, Milpied, N., additional, Castagna, L., additional, and Mohty, M., additional

Published
2014
Full Text
View/download PDF

205. B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY

Author

Roberto, A, primary, Castagna, L, additional, Gandolfi, S, additional, Zanon, V, additional, Bramanti, S, additional, Sarina, B, additional, Crocchiolo, R, additional, Todisco, E, additional, Carlo-Stella, C, additional, Tentorio, P, additional, Timofeeva, I, additional, Santoro, A, additional, Bella, S Della, additional, Roederer, M, additional, Mavilio, D, additional, and Lugli, E, additional

Published
2014
Full Text
View/download PDF

207. Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies

Author

Oudin, C., primary, Chevallier, P., additional, Furst, S., additional, Guillaume, T., additional, Cheikh, J. E., additional, Delaunay, J., additional, Castagna, L., additional, Faucher, C., additional, Granata, A., additional, Devillier, R., additional, Chabannon, C., additional, Esterni, B., additional, Vey, N., additional, Mohty, M., additional, and Blaise, D., additional

Published
2014
Full Text
View/download PDF

210. Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment

Author

Thiel, U, Koscielniak, E, Blaeschke, F, Grunewald, T G P., Badoglio, M, Diaz, M A., Paillard, C, Prete, A, Ussowicz, M, Lang, P, Fagioli, F, Lutz, P, Ehninger, G, Schneider, P, Santucci, A, Bader, P, Gruhn, B, Faraci, M, Antunovic, Petar, Styczynski, J, Krueger, W H., Castagna, L, Rohrlich, P, Ouachee-Chardin, M, Salmon, A, Peters, C, Bregni, M, Burdach, S, Thiel, U, Koscielniak, E, Blaeschke, F, Grunewald, T G P., Badoglio, M, Diaz, M A., Paillard, C, Prete, A, Ussowicz, M, Lang, P, Fagioli, F, Lutz, P, Ehninger, G, Schneider, P, Santucci, A, Bader, P, Gruhn, B, Faraci, M, Antunovic, Petar, Styczynski, J, Krueger, W H., Castagna, L, Rohrlich, P, Ouachee-Chardin, M, Salmon, A, Peters, C, Bregni, M, and Burdach, S

Abstract

Background: Allogeneic haematopoietic stem cell transplantation (allo-SCT) may provide donor cytotoxic T cell-/NK cell-mediated disease control in patients with rhabdomyosarcoma (RMS). However, little is known about the prevalence of graft-vs-RMS effects and only a few case experiences have been reported. less thanbrgreater than less thanbrgreater thanMethods: We evaluated allo-SCT outcomes of 30 European Group for Blood and Marrow Transplantation (EBMT)-registered patients with advanced RMS regarding toxicity, progression-free survival (PFS) and overall survival (OS) after allo-SCT. Twenty patients were conditioned with reduced intensity and ten with high-dose chemotherapy. Twenty-three patients were transplanted with HLA-matched and seven with HLA-mismatched grafts. Three patients additionally received donor lymphocyte infusions (DLIs). Median follow-up was 9 months. less thanbrgreater than less thanbrgreater thanResults: Three-year OS was 20% (s. e.+/- 8%) with a median survival time of 12 months. Cumulative risk of progression was 67% (s. e.+/- 10%) and 11% (s. e.+/- 6%) for death of complications. Thirteen patients developed acute graft-vs-host disease (GvHD) and five developed chronic GvHD. Eighteen patients died of disease and four of complications. Eight patients survived in complete remission (CR) (median: 44 months). No patients with residual disease before allo-SCT were converted to CR. less thanbrgreater than less thanbrgreater thanConclusion: The use of allo-SCT in patients with advanced RMS is currently experimental. In a subset of patients, it may constitute a valuable approach for consolidating CR, but this needs to be validated in prospective trials., Funding Agencies|Wilhelm Sander-Stiftung|2006.109.1|Else Kroner-Fresenius-Stiftung|P31/08//A123/07|BMBF (TranSarNet FK)|01GM087001GM1104B|Deutsche Forschungsgemeinschaft (DFG)|GR3728/2-1|AmGen and Chugai and the Deutsche Kinderkrebsstiftung|DKS 2010.07

Published
2013
Full Text
View/download PDF

211. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation

Author

Martínez, C, Canals, C, Sarina, B, Alessandrino, Ep, Karakasis, D, Pulsoni, A, Sica, Simona, Trneny, M, Snowden, Ja, Kanfer, E, Milpied, N, Bosi, A, Guidi, S, De Souza, Ca, Willemze, R, Arranz, R, Jebavy, L, Hellmann, A, Sibon, D, Oneto, R, Luan, Jj, Dreger, P, Castagna, L, Sureda, A., Sica, Simona (ORCID:0000-0003-2426-3465), Martínez, C, Canals, C, Sarina, B, Alessandrino, Ep, Karakasis, D, Pulsoni, A, Sica, Simona, Trneny, M, Snowden, Ja, Kanfer, E, Milpied, N, Bosi, A, Guidi, S, De Souza, Ca, Willemze, R, Arranz, R, Jebavy, L, Hellmann, A, Sibon, D, Oneto, R, Luan, Jj, Dreger, P, Castagna, L, Sureda, A., and Sica, Simona (ORCID:0000-0003-2426-3465)

Abstract

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care for patients with relapsed Hodgkin's lymphoma (HL). However, there is currently little information on the predictors of outcome for patients whose disease recurs after ASCT.

Published
2013

212. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

Author

Schmid, C. (Christoph), Labopin, M. (Myriam), Nagler, A. (Arnon), Niederwieser, D. (Dietger), Castagna, L. (Luca), Tabrizi, R. (Reza), Stadler, M. (Michael), Kuball, J. (Jürgen), Cornelissen, J.J. (Jan), Vorlicek, J. (Jiri), Socié, G. (Gerard), Falda, M. (M.), Vindelov, L. (Lars), Ljungman, P. (Per), Jackson, G. (Graham), Kröger, N. (Nicolaus), Rank, A. (Andreas), Polge, E. (Emmanuelle), Rocha, V. (Vanderson), Mohty, M. (Mohamad), Schmid, C. (Christoph), Labopin, M. (Myriam), Nagler, A. (Arnon), Niederwieser, D. (Dietger), Castagna, L. (Luca), Tabrizi, R. (Reza), Stadler, M. (Michael), Kuball, J. (Jürgen), Cornelissen, J.J. (Jan), Vorlicek, J. (Jiri), Socié, G. (Gerard), Falda, M. (M.), Vindelov, L. (Lars), Ljungman, P. (Per), Jackson, G. (Graham), Kröger, N. (Nicolaus), Rank, A. (Andreas), Polge, E. (Emmanuelle), Rocha, V. (Vanderson), and Mohty, M. (Mohamad)

Abstract

Because information on management and outcome of AML relapse after allogeneic hematopoietic stem cell transplantation (HSCT) with reduced intensity conditioning (RIC) is scarce, a retrospective registry study was performed by the Acute LeukemiaWorking Party of EBMT. Among 2815 RIC transplants performed for AML in complete remission (CR) between 1999 and 2008, cumulative incidence of relapse was 32% ± 1%. Relapsed patients (263) were included into a detailed analysis of risk factors for overall survival (OS) and building of a prognostic score. CR was reinduced in 32%; remission duration after transplantation was the only prognostic factor for response (P = .003). Estimated 2-year OS from relapse was 14%, thereby resembling results of AML relapse after standard conditioning. Among variables available at the time of relapse, remission after HSCT>5 months (hazard ratio [HR] = 0.50, 95% confidence

Published
2012
Full Text
View/download PDF

214. An improved Boussignac device for the delivery of non-invasive CPAP: the SUPER-Boussignac

Author

Bellani, G, Foti, G, Spagnolli, E, Castagna, L, Patroniti, N, Pesenti, A, BELLANI, GIACOMO, PATRONITI, NICOLO' ANTONINO, PESENTI, ANTONIO MARIA, FOTI, GIUSEPPE, Bellani, G, Foti, G, Spagnolli, E, Castagna, L, Patroniti, N, Pesenti, A, BELLANI, GIACOMO, PATRONITI, NICOLO' ANTONINO, PESENTI, ANTONIO MARIA, and FOTI, GIUSEPPE

Abstract

PURPOSE: The purpose of this study is to describe and test a modified Boussignac system for non-invasive continuous positive airway pressure, aimed at reducing the decrease in inspiratory oxygen fraction (FiO(2)) with higher inspiratory peak flow rates. METHODS: We modified a Boussignac circuit by inserting a T-piece between the Boussignac valve and the face mask. The T-piece was connected to a reservoir balloon receiving oxygen by an independent source. The system was tested in a bench study, consisting of five steps, with increasing inspiratory peak flow rates [Formula: see text] Three levels of PEEP were tested: 7, 10 and 13 cmH(2)O. The following devices were tested: Boussignac, Boussignac with reservoir but without supplementary oxygen, Boussignac with reservoir and 10 (SUPER-Boussignac(10)) and 30 l/min (SUPER-Boussignac(30)) of supplementary oxygen. In each step we measured FiO(2), tidal volumes, and airway pressure. RESULTS: FiO(2) increased with PEEP and decreased at increasing [Formula: see text] with all the systems. However, FiO(2) increased with SUPER-Boussignac(10) (7-10%) and with SUPER-Boussignac(30) (10-30%). Moreover, in the latter case, for [Formula: see text] values up to 60 l/min, FiO(2) became independent of [Formula: see text] The SUPER-Boussignac allowed also smaller drop in airway pressure during inspiration and higher tidal volumes. CONCLUSIONS: The SUPER-Boussignac represents a simple way to significantly improve the performance of the Boussignac device.

Published
2009

215. Leptin: adipocyte hormone

Author

Castagna, L, DE GREGORIO, T, Allegra, Alessandro, Buemi, Michele, Corsonello, A, Bonanzinga, S, Catanoso, M, Ceruso, D, and Corica, Francesco

Subjects
leptin, adipocytes, hypothalamus
Published
1998

218. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma

Author

Raiola, A, primary, Dominietto, A, additional, Varaldo, R, additional, Ghiso, A, additional, Galaverna, F, additional, Bramanti, S, additional, Todisco, E, additional, Sarina, B, additional, Giordano, L, additional, Ibatici, A, additional, Santoro, A, additional, Clavio, M, additional, Bacigalupo, A, additional, and Castagna, L, additional

Published
2013
Full Text
View/download PDF

222. Extracorporeal photochemotherapy for the treatment of chronic graft-versus-host disease: trend for a possible cell dose-related effect?

Author

Perseghin, P, Galimberti, S, Balduzzi, A, Bonanomi, S, Baldini, V, Rovelli, A, Dassi, M, Rambaldi, A, Castagna, L, Corti, P, Pogliani, E, Uderzo, C, GALIMBERTI, STEFANIA, POGLIANI, ENRICO MARIA, Uderzo, C., Perseghin, P, Galimberti, S, Balduzzi, A, Bonanomi, S, Baldini, V, Rovelli, A, Dassi, M, Rambaldi, A, Castagna, L, Corti, P, Pogliani, E, Uderzo, C, GALIMBERTI, STEFANIA, POGLIANI, ENRICO MARIA, and Uderzo, C.

Abstract

Extracorporeal photochemotherapy (ECP) has been progressively introduced into the treatment of both acute and chronic graft-versus-host disease (cGvHD) over the last decade. Nevertheless, its mechanisms of action, as well as the optimal treatment schedule, have not yet been defined. We retrospectively analyzed 25 patients with cGvHD unresponsive to conventional treatments who underwent ECP from 1997 until 2005. The impact of various factors (such as treated and infused nucleated cells, time from transplantation and cGvHD onset, and time from cGvHD and ECP treatment) on the probability of no response to ECP was therefore investigated. A positive response to ECP was achieved in 80% of the patients, after a median of 19 ECP treatments (with a range of 8-38). Eighteen out of the 20 patients responsive to the treatment maintained their response for a median of 30 months. We mainly focused on clinical response and yield composition. The analysis on mononuclear cell (MNC) dose suggested that an increase of MNC dose/kg b.w. (body weight) induced a decrease in the odds of treatment failure, and that, if the MNC dose infused was at least 100 x 10(6)/kg b.w. per ECP treatment, a more positive and longer-lasting response was achieved. Moreover, the mean dose of treated and infused monocytes x 10(6)/kg b.w./ECP did not account for a clear dose-related effect. These findings may eventually result in a more patient-tailored approach to ECP. Prospective multicenter trials should be designed to investigate the real impact of MNC dose on ECP responsiveness.

Published
2007

223. Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT

Author

Castagna, L, primary, Boubdallah, R, additional, Furst, S, additional, Coso, D, additional, El Cheikh, J, additional, Faucher, C, additional, Crocchiolo, R, additional, Granata, A, additional, Chabannon, C, additional, Lemarié, C, additional, Calmels, B, additional, Boher, J M, additional, Mohty, M, additional, and Blaise, D, additional

Published
2012
Full Text
View/download PDF

224. TLI in refractory chronic GVHD

Author

Devillier, R, primary, Castagna, L, additional, Gonzague, L, additional, El-Cheikh, J, additional, Fürst, S, additional, Faucher, C, additional, Michel, R, additional, and Blaise, D, additional

Published
2012
Full Text
View/download PDF

229. Allogeneic Stem Cell Transplantation from Matched Related Donor in Patients Over the Age of 55 Years After Reduced Intensity Conditioning Associating Fludarabine-Iv Busulfan and Rabbit-Antithymocyte Globulin: A Prospective Multicenter Phase II Clinical Trial with Socio Economic Evaluation

Author

Blaise, D., primary, Mohty, M., additional, Milpied, N., additional, Lecorroller-Soriano, A.-G., additional, Fegueux, N., additional, Furst, S., additional, Chevallier, P., additional, Tabrizi, R., additional, Michallet, M., additional, Cahn, J.-Y., additional, Bay, J.-O., additional, El Cheikh, J., additional, Faucher, C., additional, Crocchiolo, R., additional, Boyer-Chammard, A., additional, Castagna, L., additional, and Boher, J.-M., additional

Published
2012
Full Text
View/download PDF

230. Five Versus 2.5 mg/kg of Anti-Thymocyte-Globulin Dose in Reduced-Intensity-Conditioning Reduces Acute and Chronic Graft-Versus-Host Disease for Patients with Myeloid Malignancies Undergoing Allogeneic Stem Cell Transplantation

Author

Devillier, R., primary, Crocchiolo, R., additional, Castagna, L., additional, Fürst, S., additional, El Cheikh, J., additional, Faucher, C., additional, Prebet, T., additional, Etienne, A., additional, Chabannon, C., additional, Esterni, B., additional, and Blaise, D., additional

Published
2012
Full Text
View/download PDF

231. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy

Author

Devillier, R., primary, Coso, D., additional, Castagna, L., additional, Brenot Rossi, I., additional, Anastasia, A., additional, Chiti, A., additional, Ivanov, V., additional, Schiano, J. M., additional, Santoro, A., additional, Chabannon, C., additional, Balzarotti, M., additional, Blaise, D., additional, and Bouabdallah, R., additional

Published
2012
Full Text
View/download PDF

240. The Association Of Fludarabin, Oral Busulfan And Thymoglobulin Prior To Matched Related Allo-SCT Allows For High Long Term Outcome For Both Patients With Myeloid Or Lymphoid Malignancies: Long Term Analysis Of A Homogenous Cohort Of 100 Consecutive Patients

Author

Farnault, L., primary, Esterni, B., additional, Faucher, C., additional, Furst, S., additional, El Cheikh, J., additional, Ladaique, P., additional, Vey, N., additional, Bouabdallah, R., additional, Stoppa, A.M., additional, Lemarie, C., additional, Calmels, B., additional, Castagna, L., additional, Mohty, M., additional, Chabannon, C., additional, and Blaise, D., additional

Published
2010
Full Text
View/download PDF

241. Prospective Comparison of Reduced Intensity (Flu-Bu-ATG) vs. Non-Myeloablative (Flu-TBI) Conditioning For Matched Related allo-SCT: A Clinical and Cost-Effectiveness Multicenter ITAC Study (Mini vs. Micro Trial)

Author

Blaise, D., primary, Tabrizi, R., additional, Le Corroller, A.G., additional, Michallet, M., additional, Bay, J.O., additional, Mohty, M., additional, Faucher, C., additional, Milpied, N., additional, Castagna, L., additional, Boyer Chammard, A., additional, and Boher, J.M., additional

Published
2010
Full Text
View/download PDF

243. Prognostic Indexes Is Not Predictive Of Treatment Related Mortality In Patients (pts) Older Than 60 Years Treated With Reduced Intensity Conditioning And Allogeneic Stem Cell Transplantation (RIC-ALLO)

Author

Castagna, L., primary, Marchetti, N., additional, Fürst, S., additional, El-Cheikh, J., additional, Faucher, C., additional, Vey, N., additional, Bouabdallah, R., additional, Stoppa, A.-M., additional, Mohty, M., additional, Esterni, B., additional, and Blaise, D., additional

Published
2010
Full Text
View/download PDF

245. Better Outcome with Tandem High DOSE CHEMOTHERAPY and AUTOLOGOUS STEM CELLS TRANSPLANT IN Relapsed/Refractory HODGKIN LYMPHOMA PATIENTS Which Reached COMPLETE REMISSION AFTER Ifosfamide- Gemcitabine-Vinorelbine Scheme (IGEV).

Author

Anastasia, Antonella, primary, Balzarotti, Monica, additional, Magagnoli, Massimo, additional, Spina, Michele, additional, Mazza, Rita, additional, Castagna, L., additional, Nozza, Andrea, additional, Bramanti, Stefania, additional, Giordano, Laura, additional, Tirelli, Umberto, additional, and Santoro, Armando, additional

Published
2009
Full Text
View/download PDF

249. Infusion of suicide gene-modified donor T cells promotes a rapid and effective immune reconstitution and provides long-term survival after haploidentical hemaopoietic cell transplantation for the cure of patients with high-risk leukemia

Author

Bonini, C., primary, Ciceri, F., additional, Lupo Stanghellini, M.T., additional, Bondanza, A., additional, Magnani, Z., additional, Perna, S., additional, Bernardi, M., additional, Peccatori, J., additional, Servida, P., additional, Crippa, F., additional, Kaneko, S., additional, Valtolina, V., additional, Ferrari, M., additional, Provasi, E., additional, Salomoni, M., additional, Turchetto, L., additional, Toma, S., additional, Traversari, C., additional, Bruzzi, P., additional, Castagna, L., additional, Santoro, A., additional, Apperley, J., additional, Slavin, S., additional, Colombi, S., additional, Gallo Stampino, C., additional, Bregni, M., additional, and Bordignon, C., additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results